BioVantra
Client Portal Request Information →
Resources / Integrated Urothelial Cytomolecular Testing Overview

Integrated Urothelial
Cytomolecular Testing Overview.

BioVantra’s Integrated Urothelial Cytomolecular Testing brings urine cytology, multi-target FISH, structured enumeration, and clinical correlation together into a single report. The goal is not simply to report separate urine-based findings, but to organize morphologic and molecular information into one consistent interpretation that supports bladder cancer detection and surveillance — alongside cystoscopy, biopsy, imaging, and clinical judgment.

Request Information → View service page
Topic
Clinical overview
Service
Integrated Urothelial Cytomolecular Testing
Audience
Urologists & clinical teams
01 · What urine cytology contributes

Morphologic review
of urothelial cells.

Urine cytology provides the morphologic foundation of the integrated interpretation. A voided urine specimen is reviewed cytologically for the cellular features of shed urothelial cells, with attention to nuclear and cytoplasmic changes that may indicate atypical or suspicious cells and warrant molecular correlation.

A

Morphologic evaluation of urothelial cells

Cytologic review describes the cellular and nuclear features of urothelial cells shed into the urine, including cell size, nuclear-to-cytoplasmic ratio, chromatin pattern, and nuclear contour.

B

Identification of atypical or suspicious cells

Cytology supports detection and characterization of atypical urothelial cells and cells suspicious for urothelial carcinoma, guiding downstream molecular interpretation and clinical correlation.

C

Morphologic foundation for integrated interpretation

The cytologic read is not delivered in isolation. It is the morphologic anchor that is reviewed alongside multi-target FISH so that cellular and molecular findings inform one another within a single case.

02 · What multi-target FISH contributes

Molecular evidence
cytology alone cannot provide.

Multi-target fluorescence in situ hybridization adds molecular evidence of chromosomal abnormalities associated with urothelial carcinoma. The assay evaluates aneuploidy of chromosomes 3, 7, and 17 and loss of the 9p21 locus — findings that may be present in urothelial cells that appear cytologically unremarkable.

  • A

    Molecular evidence of chromosomal abnormalities

    FISH interrogates urothelial cells for chromosomal aberrations commonly seen in urothelial carcinoma, contributing molecular evidence of malignancy beyond what morphology can resolve alone.

  • B

    Four complementary targets

    The assay evaluates four loci together: pericentromeric probes for chromosomes 3, 7, and 17, and a locus-specific probe for 9p21. Each probe reports on a different dimension of the cell’s chromosomal state.

  • C

    Adds information cytology may not provide

    Chromosomal abnormalities can be present in urothelial cells that appear morphologically unremarkable. FISH can surface molecular changes in cases where cytology is negative, atypical, or equivocal.

  • D

    Interpreted alongside cytology

    FISH results are not reported in isolation. They are reviewed on the same case as the cytologic findings so that morphologic and molecular information inform one another.

03 · What the enumeration summary means

Structured counting,
consistent interpretation.

The report enumerates consecutive non-inflammatory urothelial cells rather than drawing conclusions from isolated abnormal cells. Each cell is classified against defined chromosomal criteria so that the molecular read is reproducible and organized for clinical review.

A

Consecutive non-inflammatory cells

Signals are enumerated across consecutive non-inflammatory urothelial cells. This consistent denominator reduces the influence of isolated abnormal cells and supports a more reproducible molecular read across cases.

B

Multi-chromosome gains

Cells showing gains in two or more of chromosomes 3, 7, or 17 are categorized as multi-chromosome gains. This pattern is the most informative FISH finding for detection of urothelial carcinoma.

C

Single gains and tetrasomy

Single-chromosome gains and tetrasomy (four copies of multiple chromosomes) are counted separately. These patterns are reported alongside the cytology and reviewed with appropriate clinical caution.

D

9p21 (homozygous loss)

Cells with homozygous loss of the 9p21 locus are enumerated separately. 9p21 loss is a recognized early event in urothelial carcinoma and is interpreted within the broader cytomolecular context.

E

Consistent molecular interpretation

Enumeration by category produces a structured summary that is easier to read, document, and compare across specimens — supporting consistent molecular interpretation within a case and across longitudinal surveillance.

04 · Integrated interpretation and clinical correlation

Cytology, molecular,
and clinical context.

The report organizes what is seen cytologically, what is measured molecularly, and what the combined findings may be most consistent with clinically. Localization still requires correlation with cystoscopy, biopsy, imaging, and the broader clinical setting — disease may involve the lower urinary tract or the upper urinary tract.

  • A

    What is seen cytologically

    The cytologic read is summarized in its own right — negative, atypical, suspicious, or positive for malignancy — so the morphologic finding is clearly stated before molecular context is added.

  • B

    What is measured molecularly

    The structured enumeration summary presents the multi-target FISH findings in one place: multi-chromosome gains, single gains, tetrasomy, and 9p21 loss, reviewed against defined thresholds.

  • C

    What the combined findings suggest

    Cytologic and molecular findings are read together and expressed as a concise integrated interpretation — most consistent with a benign, indeterminate, suspicious, or positive read, depending on the case.

  • D

    Suspicious or positive findings

    Suspicious or positive findings can support clinical concern for clinically significant urothelial disease. They are not a localization or a diagnosis in themselves and are interpreted within the full clinical context.

  • E

    Localization still requires correlation

    A urine specimen reflects cells shed along the urinary tract. Localization of disease — including whether findings relate to the lower or upper urinary tract — requires correlation with cystoscopy, biopsy, imaging, and clinical judgment.

05 · Detection, surveillance, and follow-up use cases

Practical use
across the care pathway.

Integrated urothelial cytomolecular testing is used across the bladder cancer pathway — from initial workup of suspicious findings through long-term surveillance and post-treatment follow-up. In each setting, the report is intended to contribute structured urine-based information rather than stand alone as a diagnosis.

A

Detection and workup

Integrated urine testing may be used during the workup of patients with hematuria or other clinical findings suggestive of urothelial carcinoma, contributing cytomorphologic and molecular urine information to the broader evaluation.

B

Surveillance after a bladder cancer diagnosis

In patients with a prior diagnosis of non-muscle-invasive bladder cancer, integrated urine testing can support longitudinal surveillance by providing structured cytomolecular information that may be compared across visits.

C

Recurrence monitoring

Structured cytomolecular findings may support monitoring for recurrence over time and can be reviewed alongside cystoscopic, imaging, and tissue-based evaluations that remain central to the surveillance pathway.

D

Post-treatment follow-up

After treatment — including intravesical therapy — integrated urine testing can contribute cytomolecular information to follow-up, with appropriate caution given the potential for treatment-related cytologic and molecular changes.

E

Suspicious or equivocal cytology

When urine cytology is atypical, suspicious, or otherwise equivocal, the integrated molecular read may help frame the finding for clinical discussion and further workup without replacing tissue-based confirmation.

06 · Relationship to cystoscopy, biopsy, imaging, and clinical judgment

Additive, integrative,
not a replacement.

Integrated urothelial cytomolecular testing is intended to work alongside existing bladder cancer diagnostic and surveillance pathways. It does not replace cystoscopy, biopsy, imaging, or physician judgment. Its contribution is the way urine-based morphologic and molecular information is organized and reported.

  • A

    Complements cystoscopy

    Cystoscopy remains central to direct visualization of the bladder and identification of mucosal lesions. The integrated urine report is intended to sit alongside cystoscopic findings, not to stand in for them.

  • B

    Complements biopsy and histopathology

    Definitive diagnosis of urothelial carcinoma rests on tissue-based evaluation. The urothelial cytomolecular report contributes information from shed cells, but does not replace biopsy and histopathologic review.

  • C

    Complements imaging

    Imaging of the urinary tract — including upper-tract imaging where indicated — is used to localize and characterize disease. Integrated urine findings can be read alongside imaging but do not localize disease on their own.

  • D

    Integrated urine information, not localization

    The report provides integrated urine-based cytomolecular information. Any inference about where along the urinary tract findings originate remains a clinical decision based on the broader evaluation.

  • E

    Additive within established pathways

    Integrated urothelial cytomolecular testing should be understood as additive to, not a substitute for, established components of the bladder cancer diagnostic and surveillance pathway.

07 · Practical clinical value

What a referring urologist
can expect to use.

In day-to-day use, the integrated urothelial cytomolecular report surfaces a short list of practical takeaways that referring urologists can read alongside the rest of the clinical picture.

A

Integrated communication

Cytologic and molecular findings are communicated together in a single report so referring clinicians can read them in context rather than across disparate results.

B

Structured reporting

Enumeration categories and interpretive language follow a consistent structure, making each report easier to read, reference, and discuss across teams.

C

Organized morphologic and molecular findings

Cytology, multi-target FISH, and the integrated interpretation are organized into clearly labeled sections so the morphologic and molecular contributions are visible in one place.

D

Longitudinal comparison during surveillance

Consistent categorization makes it easier to compare serial reports over the course of surveillance, supporting clinicians in following trends across visits.

E

Clinically useful framing of suspicious or positive results

Suspicious or positive findings are framed in terms that support clinical discussion and correlation — acknowledging the significance of the finding while respecting the role of cystoscopy, biopsy, imaging, and physician judgment.

Downloadable PDFs

Download physician-facing PDF materials related to Integrated Urothelial Cytomolecular Testing and report interpretation.

PDF 01

Integrated Urothelial Cytomolecular Testing Overview

A concise physician-facing overview of the service, report structure, and clinical value.

Open PDF →
PDF 02

Curated Clinical Case & Sample Report

A physician-facing case companion followed by a sample Integrated Urothelial Cytomolecular Report.

Open PDF →
08 · Selected references

Selected references.

A short, non-exhaustive list of peer-reviewed literature on multi-target urinary FISH in bladder cancer detection, surveillance, and post-treatment follow-up, provided for clinical reference.

  1. Kipp, B.R., et al. (2005). Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. Journal of Urology, 173(2), 401–404.
  2. Kipp, B.R., et al. (2009). Quantitative fluorescence in situ hybridization and its ability to predict bladder cancer recurrence and progression to muscle-invasive bladder cancer. Journal of Molecular Diagnostics, 11(2), 148–154.
  3. Zellweger, T., et al. (2006). Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer. International Journal of Cancer, 119(7), 1660–1665.
  4. Bollmann, M., et al. (2005). Quantitative molecular urinary cytology by fluorescence in situ hybridization: a tool for tailoring surveillance of patients with superficial bladder cancer? BJU International, 95(9), 1219–1225.
  5. Sarosdy, M.F., et al. (2002). Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. Journal of Urology, 168(5), 1950–1954.
  6. Yoder, B.J., et al. (2007). Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology. American Journal of Clinical Pathology, 127(2), 295–301.
Connect with BioVantra

Talk to us about integrated bladder diagnostics.

We work with urology practices and clinical teams involved in bladder cancer detection and surveillance. Share a little about your setting and a member of our team will follow up to discuss how this service may fit into your workflow.

Request Information → Contact our team
Existing client? Access diagnostic reports and case history through the Client Portal
Emailcontact@biovantra.com
Phone(352) 861-2296
Fax(352) 671-2737
Address9401 SW Highway 200
STE 502
Ocala, FL 34481-9650